Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of low-dose topiramate on language function in children with migraine

  • Han, Seung-A (Department of Pediatrics, Chonbuk National University Medical School) ;
  • Yang, Eu Jeen (Department of Pediatrics, Pusan National University Children's Hospital) ;
  • Kong, Younghwa (Department of Pediatrics, Chonbuk National University Medical School) ;
  • Joo, Chan-Uhng (Department of Pediatrics, Chonbuk National University Medical School) ;
  • Kim, Sun Jun (Department of Pediatrics, Chonbuk National University Medical School)
  • Received : 2017.03.22
  • Accepted : 2017.05.30
  • Published : 2017.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: This study aimed to verify the safety of low-dose topiramate on language development in pediatric patients with migraine. Methods: Thirty newly diagnosed pediatric patients with migraine who needed topiramate were enrolled and assessed twice with standard language tests, including the Test of Language Problem Solving Abilities (TOPs), Receptive and Expressive Vocabulary Test, Urimal Test of Articulation and Phonology, and computerized speech laboratory analysis. Data were collected before treatment, and topiramate as monotherapy was sustained for at least 3 months. The mean follow-up period was $4.3{\pm}2.7months$. The mean topiramate dosage was 0.9 mg/kg/day. Results: The patient's mean age was $144.1{\pm}42.3months$ (male-to-female ratio, 9:21). The values of all the language parameters of the TOPs were not changed significantly after the topiramate treatment as follows: Determine cause, from $15.0{\pm}4.4$ to $15.4{\pm}4.8$ (P>0.05); making inference, from $17.6{\pm}5.6$ to $17.5{\pm}6.6$ (P>0.05); predicting, from $11.5{\pm}4.5$ to $12.3{\pm}4.0$ (P>0.05); and total TOPs score, from $44.1{\pm}13.4$ to $45.3{\pm}13.6$ (P>0.05). The total mean length of utterance in words during the test decreased from $44.1{\pm}13.4$ to $45.3{\pm}13.6$ (P<0.05). The Receptive and Expressive Vocabulary Test results decreased from $97.7{\pm}22.1$ to $96.3{\pm}19.9months$, and from $81.8{\pm}23.4$ to $82.3{\pm}25.4months$, respectively (P>0.05). In the articulation and phonology validation in both groups, speech pitch and energy were not significant, and all the vowel test results showed no other significant values. Conclusion: No significant difference was found in the language-speaking ability between the patients; however, the number of vocabularies used decreased. Therefore, topiramate should be used cautiously for children with migraine.

Keywords

References

  1. Hershey AD. Migraine. In: Kliegman RM, Stanton BF, St. Geme JW III, Schor NF, Behrman RE, editors. Nelson textbook of pediatrics. 20th ed. Philadelphia: Elsevier/Saunders, 2011:2040-5.
  2. Split W, Neuman W. Epidemiology of migraine among students from randomly selected secondary schools in Lodz. Headache 1999;39:494-501. https://doi.org/10.1046/j.1526-4610.1999.3907494.x
  3. Lee LH, Olness KN. Clinical and demographic characteristics of migraine in urban children. Headache 1997;37:269-76. https://doi.org/10.1046/j.1526-4610.1997.3705269.x
  4. Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996;37:539-43. https://doi.org/10.1111/j.1528-1157.1996.tb00606.x
  5. Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 1996;46:1684-90. https://doi.org/10.1212/WNL.46.6.1684
  6. Privitera M, Fincham R, Penry J, Reife R, Kramer L, Pledger G, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 1996;46:1678-83. https://doi.org/10.1212/WNL.46.6.1678
  7. Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-24. https://doi.org/10.1016/S0920-1211(96)00029-0
  8. Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37:763-8. https://doi.org/10.1111/j.1528-1157.1996.tb00649.x
  9. Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005;6:373-81. https://doi.org/10.1016/j.yebeh.2005.01.002
  10. Tang Y, Xia W, Yu X, Zhou B, Wu X, Lui S, et al. Altered cerebral activity associated with topiramate and its withdrawal in patients with epilepsy with language impairment: an fMRI study using the verb generation task. Epilepsy Behav 2016;59:98-104. https://doi.org/10.1016/j.yebeh.2016.03.013
  11. Coppola F, Rossi C, Mancini ML, Corbelli I, Nardi K, Sarchielli P, et al. Language disturbances as a side effect of prophylactic treatment of migraine. Headache 2008;48:86-94.
  12. Bae SY, Lim SS, Lee JH. Test of problem solving. Seoul: Seoul Community Rehabilitation Center, 2005.
  13. Kim SJ, Kim MY, Choi YM, Song MK. Effects of topiramate on language functions in newly diagnosed pediatric epileptic patients. Pediatr Neurol 2014;51:324-9. https://doi.org/10.1016/j.pediatrneurol.2014.05.033
  14. Kim YT, Hong GH, Kim KH. Content and reliability analyses of the receptive and expressive vocabulary test (REVT). Commun Sci Disord 2009;14:34-45.
  15. KimYT, Shin MJ. Urimal Test of Articulation and Phonology (U-TAP). Seoul: Hakjisa, 2004.
  16. Silberstein SD. Topiramate in migraine prevention. Headache 2005;45 Suppl 1:S57-65. https://doi.org/10.1111/j.1526-4610.2005.4501005.x
  17. Storey JR, Calder CS, Hart DE, Potter DL. Topiramate in migraine prevention: a double-blind, placebo-controlled study. Headache 2001;41:968-75. https://doi.org/10.1046/j.1526-4610.2001.01190.x
  18. Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005;45 Suppl 1:S66-73. https://doi.org/10.1111/j.1526-4610.2005.4501007.x
  19. Winner P, Pearlman EM, Linder SL, Jordan DM, Fisher AC, Hulihan J, et al. Topiramate for migraine prevention in children: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:1304-12. https://doi.org/10.1111/j.1526-4610.2005.00262.x
  20. Lakshmi CV, Singhi P, Malhi P, Ray M. Topiramate in the prophylaxis of pediatric migraine: a double-blind placebo-controlled trial. J Child Neurol 2007;22:829-35. https://doi.org/10.1177/0883073807304201
  21. Fallah R, Akhavan Karbasi S, Shajari A, Fromandi M. The efficacy and safety of topiramate for prophylaxis of migraine in children. Iran J Child Neurol 2013;7:7-11.
  22. Diamond M, Dahlof C, Papadopoulos G, Neto W, Wu SC. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005;45:1023-30. https://doi.org/10.1111/j.1526-4610.2005.05183.x
  23. Bussone G, Diener HC, Pfeil J, Schwalen S. Topiramate 100 mg/day in migraine prevention: a pooled analysis of double-blind randomised controlled trials. Int J Clin Pract 2005;59:961-8. https://doi.org/10.1111/j.1368-5031.2005.00612.x
  24. Shaygannejad V, Janghorbani M, Ghorbani A, Ashtary F, Zakizade N, Nasr V. Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 2006;46:642-8. https://doi.org/10.1111/j.1526-4610.2006.00413.x
  25. Marino SE, Pakhomov SV, Han S, Anderson KL, Ding M, Eberly LE, et al. The effect of topiramate plasma concentration on linguistic behavior, verbal recall and working memory. Epilepsy Behav 2012;24:365-72. https://doi.org/10.1016/j.yebeh.2012.04.120
  26. Ijff DM, Aldenkamp AP. Cognitive side-effects of antiepileptic drugs in children. Handb Clin Neurol 2013;111:707-18.
  27. Baeta E, Santana I, Castro G, Goncalves S, Goncalves T, Carmo I, et al. Cognitive effects of therapy with topiramate in patients with refractory partial epilepsy. Rev Neurol 2002;34:737-41.
  28. de Araujo Filho GM, Pascalicchio TF, Lin K, Sousa PS, Yacubian EM. Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav 2006;8:606-9. https://doi.org/10.1016/j.yebeh.2006.01.016